B cells in systemic sclerosis: A possible target for therapy

Autoimmunity Reviews

Volumn 10, Issue 10, 2011, Pages 624-630

  Bosello, Silvia ^a   De Luca, Giacomo ^a   Tolusso, Barbara ^a   Lama, Gina ^a   Angelucci, Cristiana ^a   Sica, Gigliola ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti CD20; B cells; Cytokines; Rituximab; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CD19 ANTIGEN; COLLAGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; GENETIC MODEL; HUMAN; INFECTION COMPLICATION; INJECTION SITE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, MUTANT STRAINS; MOLECULAR TARGETED THERAPY; SCLERODERMA, SYSTEMIC;

EID: 80051607473     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.013     Document Type: Review

References (66)

1. Gu Y.S., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008, 38:132-160.
2. Derk C.T., Jimenez S.A. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003, 2:181-191.
3. Furst D.E., Clements P.J. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997, 24:53-57.
4. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10:65-73.
5. Chizzolini C., Brembilla N.C., Montanari E., Truchetet M.E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011, 10:276-281.
6. Famularo G., Giacomelli R., Alesse E., Cifone M.G., Morrone S., Boirivant M., et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989, 29:59-63.
7. Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
8. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
9. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
10. Asano N., Fujimoto M., Yazawa N., Shirasawa S., Hasegawa M., Okochi H., et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004, 165:641-650.
11. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
12. Smith V., Van Praet J.T., Vandooren B.R., Van der Cruyssen B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197.
13. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with Rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583.
14. Bosello S., De Santis M., Lama G., Spanò C., Angelucci C., Tolusso B., et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in a thirty-six months follow-up-open label trial. Arthritis Res Therapy 2010, 12:R54.
15. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010, 49:271-280.
16. Daoussis D., Liossis S., Tsamandas A., Kalogeropoulou C., Kazantzi A., Korfiatis P., et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010, 40:127-136.
17. McGonagle D., Tan A.L., Madden J., Rawstron A.C., Rehman A., Emery P., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with Rituximab. Rheumatology 2008, 47:552-553.
18. Yoo W. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with Rituximab. Rheumatol Int 2010, 8. Epub ahead of print.
19. Fabri M., Hunzelmann N., Krieg T., Rubbert A. Discordant response to Rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 2008, 58:S127-S128.
20. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
21. Hasegawa M. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010, 37:3-10.
22. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008, 20:707-712.
23. Wynn T.A. Fibrotic disease and the T(H)1 /T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
24. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin-6. J Invest Dermatol 1991, 97:686-692.
25. Macatonia S.E., Hosken N.A., Litton M., Vieira P., Hsieh C.S., Culpepper J.A., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079.
26. Stockinger B., Zal T., Zal A., Gray D. B cells solicit their own help from T cells. J Exp Med 1996, 83:891-899.
27. Mason D. The role of B cells in the programming of T cells for IL-4 synthesis. J Exp Med 1996, 183:717-719.
28. Skok J., Poudrier J., Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 1999, 163:4284-4291.
29. Rincon M., Anguita J., Nakamura T., Fikrig E., Flavell R.A. Interleukin (IL)-6 directs the differentiation of IL-4- producing CD4+ T cells. J Exp Med 1997, 185:461-469.
30. Hsieh C.S., Heimberger A.B., Gold J.S., O'Garra A., Murphy K.M. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell receptor transgenic system. Proc Natl Acad Sci USA 1992, 89:6065-6069.
31. Kishimoto T. The biology of interleukin-6. Blood 1989, 74:1-10.
32. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546.
33. Hasegawa M., Sato S., Fujimoto M., Ihn H., Kikuchi K., Takehara K. Serum levels of Interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998, 25:308-316.
34. De Santis M., Bosello S., La Torre G., Capuano A., Tolusso B., Pagliari G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005, 6:96-106.
35. Koch A.E., Kronfeld-Harrington L.B., Szekanecz Z., Cho M.M., Haines G.K., Harlow L.A., et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993, 61:239-246.
36. Kadono T., Kikuchi K., Ihn H., Takehara K., Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998, 25:296-301.
37. Kondo K., Okada T., Matsui T., Kato S., Date K., Yoshihara M., et al. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001, 13:220-226.
38. Snapper C.M., Waegell W., Beernink H., Dasch J.R. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J Immunol 1993, 151:4625-4636.
39. Green M.C., Sweet H.O., Bunker L.E. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976, 82:493-512.
40. Bona C., Rothfield N. Autoantibodies in scleroderma and tight skin mice. Curr Opin Immunol 1994, 6:931-937.
41. Zhou L.J. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol Cell Biol 1994, 14:3884-3894.
42. Matsushita T., Fujimoto M., Hasegawa M., Matsushita Y., Komura K., Ogawa F., et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127:2772-2780.
43. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
44. Yoshizaki A., Iwata Y., Komura K., Ogawa F., Hara T., Muroi E., et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172:1650-1663.
45. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL 10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
46. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41:1123-1133.
47. Tsuchiya N., Kuroki K., Fujimoto M., Murakami Y., Tedder T.F., Tokunaga K., et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004, 50:4002-4007.
48. Hitomi Y., Tsuchiya N., Hasegawa M., Fujimoto M., Takehara K., Tokunaga K., et al. Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. Tissue Antigens 2007, 69:242-249.
49. Wang J., Watanabe T. Expression and function of Fas during differentiation and activation of B cells. Intern Rev Immunol 1999, 18:367-379.
50. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324.
51. Hussein M.R., Hassan H.I., Hofny E.R.M., Elkholy M., Fatehy N.A., Abd Elmoniem A.E.A., et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ cells, interleukin-1β, and tumor necrosis factor-α in the bronchoalveolar lavage fluid, pheripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005, 58:178-184.
52. Krailing B.M., Maul G., Jimenez S.A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiol 1995, 63:48-56.
53. Roumm A., Whiteside T.L., Medseger T., Rodnan G. Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27:645-653.
54. Lafyatis R., O'Hara C., Feghali-Bostwick C.A., Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56:3167-3168.
55. De Santis M., Bosello S.L., Peluso G., Pinnelli M., Alivernini S., Zizzo G., et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 2010, 10.1111/j.1752-699X.2010.00228.
56. Arnett F. Is scleroderma an autoantibody mediated disease?. Curr Opin Rheumatol 2006, 18:579-581.
57. Gabrielli A., Svegliati S., Moroncini G., Avvedimento E. Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 2007, 19:640-645.
58. Sgonc R., Gruschwitz M.S., Boeck G., Sepp N., Gruber J., Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
59. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis. Nat Med 2000, 10:1183-1186.
60. Lunardi C., Dolcino M., Peterlana D., Bason C., Navone R., Tamassia N., et al. Antibodies againsthuman cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 2006, 3:e2.
61. Ronda N., Gatti R., Giacosa R., Raschi E., Testoni C., Meroni P.L., et al. Antifibroblast antibodies from sistemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum 2002, 46:1595-1601.
62. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
63. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. PDGF and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS-ERK-Ras signalling in systemic sclerosis fibroblasts. J Biol Chem 2005, 280:36474-36482.
64. Gabrielli A., Svegliati S., Moroncini G., Luchetti M., Tonnini C., Avvedimento E.V. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev 2007, 7:121-126.
65. McSweeney P.A., Nash R.A., Sullivan K.M., Storek J., Crofford L.J., Dansey R., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002, 100:1602-1610.
66. Tyndall A., Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003, 3:1041-1049.